Adaptations to Aggressive Lymphoma Management

High priority

Your appointment may be a high priority if:

• You are due to undergo curative treatment for aggressive lymphoma. In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required, without affecting the curative potential of the treatment. Your doctor may also decide to change your planned regimen to a less myelosuppressive one. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
• You have been diagnosed with relapsed diffuse large B-cell lymphoma (DLBCL) and are scheduled to receive high-dose chemotherapy with autologous stem cell support
• You are receiving treatment as part of a clinical trial
• You have refractory DLBCL and are scheduled to receive CAR-T cell therapy

Medium priority

Your appointment may be a medium priority if:

• 

  You are scheduled to receive non-curative treatment, such as systemic therapy for relapsed aggressive lymphoma that is not eligible for autologous stem cell support. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia.  Drugs that suppress T cells (e.g. bendamustine) will be avoided
• You are due to receive prophylactic treatment with high-dose methotrexate, high-dose cytarabine and/or intrathecal methotrexate. These treatments may be cancelled during the COVID-19 pandemic
• You are due to receive palliative radiotherapy or consolidation radiotherapy. These treatments may be delayed

High priority

Your appointment may be a high priority if:

• You are due to undergo first-line treatment for mantle cell lymphoma (MCL). In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required. You may also receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
• You are receiving treatment as part of a clinical trial

Medium priority

Your appointment may be a medium priority if:

• You are scheduled to receive systemic therapy for relapsed MCL. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia, and drugs that suppress T cells (e.g. bendamustine) will be avoided

• 

  You are scheduled to receive high-dose chemotherapy with autologous stem cell support as consolidation therapy. This treatment may be delayed
• You are due to receive maintenance therapy with rituximab. This treatment may be delayed
• You are due to receive palliative radiotherapy. This treatment may be delayed

High priority

Your appointment may be a high priority if:

• You are due to undergo first-line treatment for aggressive T-cell lymphoma. In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required. You may also receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
• You are receiving treatment as part of a clinical trial

Medium priority

Your appointment may be a medium priority if:

• 

  You are scheduled to receive systemic therapy for relapsed aggressive T-cell lymphoma. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia, and drugs that suppress T cells (e.g. bendamustine) will be avoided
• You are scheduled to receive high-dose chemotherapy with autologous stem cell support as consolidation therapy. This treatment may be delayed
• You are due to receive palliative radiotherapy. This treatment may be delayed